Childhood Acute Lymphoblastic Leukemia Treatment–for health professionals (PDQ®)

SECTIONS

Changes to this Summary (12/10/2015)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Risk-Based Treatment Assignment

Added text about minimal residual disease (MRD) levels obtained 10 to 12 weeks after the start of treatment (end-consolidation) that have also been shown to be prognostically important; patients with high levels of MRD at this time point have a significantly inferior event-free survival compared with other patients.

Postinduction Treatment for Specific ALL Subgroups

Added text to state that for infants with acute lymphoblastic leukemia (ALL) who undergo transplantation in first complete remission, outcomes appear to be similar with non–total-body irradiation (TBI) regimens and TBI-based regimens (cited Kato et al. as reference 25).

Added text about a trial conducted in Japan in which 139 patients aged 15 to 24 years with Philadelphia chromosome–negative ALL were treated with a high-risk pediatric regimen (cited Hayakawa et al. as reference 39).

This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Treatment of Relapsed Childhood ALL

Next section >
About This PDQ Summary